	US 12,226,461 B2
	Chimeric endolysin polypeptide, cluster 3b
Fritz Eichenseher, Baar (DE); Mathias Schmelcher, Baar (DE); and Christian Alexander Rohrig, Baar (DE)
Assigned to Micreos Pharmaceuticals AG, Baar (CH)
Filed by Micreos Pharmaceuticals AG, Baar (DE)
Filed on May 10, 2023, as Appl. No. 18/314,864.
Application 18/314,864 is a division of application No. PCT/EP2023/055393, filed on Mar. 3, 2023.
Claims priority of application No. 22160212 (EP), filed on Mar. 4, 2022.
Prior Publication US 2024/0293517 A1, Sep. 5, 2024
Int. Cl. A61K 38/47 (2006.01); A61K 8/66 (2006.01); A61P 31/04 (2006.01); A61Q 17/00 (2006.01)

CPC A61K 38/47 (2013.01) [A61K 8/66 (2013.01); A61P 31/04 (2018.01); A61Q 17/005 (2013.01); C12Y 302/01017 (2013.01)]

13 Claims

1. An endolysin polypeptide that has lytic activity for Staphylococcus, said endolysin polypeptide comprising a polypeptide having an amino acid sequence that has at least 91% sequence identity over the entire length of SEQ ID NO: 5, wherein the endolysin polypeptide has increased lytic activity for Staphylococcus aureus ATCC 12600 at a concentration of 100 ng/ml as compared to the endolysin polypeptide with the amino acid sequence as set forth in SEQ ID NO: 2.